A recent in vitro study examined how widely used sweeteners affect gut microbes and whether combinations with common compounds or drugs change those effects. Past research and health guidance have linked artificial sweeteners to changes in the gut microbiome and to associations with conditions such as heart disease, stroke, type 2 diabetes, metabolic syndrome, cognitive decline, chronic kidney disease, and cancer, prompting investigation of underlying molecular mechanisms. The authors framed their work as a way to identify direct effects of individual sweetener compounds and mixtures on bacterial growth and metabolism.
Researchers grew 25 different gut bacterial species in the laboratory, selecting species that are considered beneficial, harmful, or neutral. They then exposed each bacterial species to a panel of 39 commercially used sweeteners. The panel included common artificial sweeteners (for example, aspartame, saccharin, and sucralose), natural sweeteners (including monk fruit derivatives, stevia components, and sucrose), and sugar alcohols such as sorbitol, maltitol, erythritol, and xylitol.
Co-lead author Kiran Raosaheb Patil, PhD, explained that the goal was to probe molecular mechanisms by which sweeteners might affect physiological processes via effects on microbial growth. The study used bacterial culture models to measure how each compound altered proliferation of the tested species.
At the end of the experiments, researchers reported that approximately 75% of the 39 sweeteners influenced the growth of at least one bacterial species in vitro. Some compounds slowed growth, while others halted growth in specific microbes. The investigators cautioned that these are laboratory results and that translation to human biology is not yet established. They recommended that future cohort and clinical studies consider direct effects on bacterial growth and metabolism when assessing sweetener impact on the microbiome.
The team also evaluated mixture effects by testing each sweetener together with common food compounds (such as caffeine and vanillin) and with eight commonly used medications. Across these combinations researchers observed more than 100 interactions that altered bacterial growth compared with single-compound exposures.
A highlighted finding was a synergistic interaction between a stevia-derived compound, isosteviol, and the antidepressant duloxetine. In combination these two compounds suppressed two bacterial species that play roles in maintaining a healthy digestive ecosystem. The authors noted isosteviol is a derivative included to broaden chemical scope rather than a primary sweetener itself. Patil emphasized that such mixture effects merit investigation in future clinical studies and that the observed interactions are not, at this stage, proven to be harmful or beneficial in humans.
External clinicians quoted in the source emphasized the study’s comprehensiveness as an in vitro screen but underscored limitations. A board-certified gastroenterologist described the research as one of the most thorough laboratory assessments of sweetener–microbiome effects to date but stressed that animal models and human trials are required to determine whether similar alterations occur in people and to establish clinical relevance. The study authors and commentators agree further work is necessary before making clinical or dietary recommendations based on these laboratory findings.
The source article summarized practical guidance from a registered dietitian for people who wish to lower intake of commercially used sweeteners. Recommendations reported in the article include:
Choose water flavored with citrus, cucumber, berries, or herbs, or opt for sparkling water instead of artificially sweetened beverages.
If using sweeteners in coffee or tea, decrease the amount gradually over several weeks rather than stopping abruptly to retrain the palate.
Read ingredient lists and labels to identify products that contain sweeteners and log daily intake to target sources for reduction.
The registered dietitian suggested gradual, sustainable changes and tailoring steps to individual preferences, rather than complete elimination of sweeteners at once.
Note on limitations and next steps: The study used in vitro bacterial culture models and therefore cannot by itself determine effects in humans. The source explicitly states that animal and human studies are needed to assess whether laboratory findings translate to the human gut and to evaluate potential clinical consequences of sweetener exposure and drug–sweetener interactions.